> Detailanzeige
Speich, Benjamin;
Chammartin, Frédérique;
Abela, Irene A;
Amico, Patrizia;
Stoeckle, Marcel P;
Eichenberger, Anna L;
Hasse, Barbara;
Braun, Dominique L;
Schuurmans, Macé M;
Müller, Thomas F;
Tamm, Michael;
Audigé, Annette;
Mueller, Nicolas J;
Rauch, Andri;
Günthard, Huldrych F;
Koller, Michael T;
Trkola, Alexandra;
Briel, Matthias;
Kusejko, Katharina;
Bucher, Heiner C;
Aebi-Popp, I A;
Anagnostopoulos, K;
Battegay, A;
Bernasconi, M;
[...]
Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial
Teilen
Literatur-
verwaltung
Direktlink
Zur
Merkliste
Lösche von
Merkliste
Per Email teilen
Auf Twitter teilen
Auf Facebook teilen
Per Whatsapp teilen
- Medientyp: E-Artikel
- Titel: Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial
- Beteiligte: Speich, Benjamin; Chammartin, Frédérique; Abela, Irene A; Amico, Patrizia; Stoeckle, Marcel P; Eichenberger, Anna L; Hasse, Barbara; Braun, Dominique L; Schuurmans, Macé M; Müller, Thomas F; Tamm, Michael; Audigé, Annette; Mueller, Nicolas J; Rauch, Andri; Günthard, Huldrych F; Koller, Michael T; Trkola, Alexandra; Briel, Matthias; Kusejko, Katharina; Bucher, Heiner C; Aebi-Popp, I A; Anagnostopoulos, K; Battegay, A; Bernasconi, M; [...]
-
Erschienen:
Oxford University Press (OUP), 2022
- Erschienen in: Clinical Infectious Diseases
- Sprache: Englisch
- DOI: 10.1093/cid/ciac169
- ISSN: 1537-6591; 1058-4838
- Entstehung:
- Anmerkungen:
- Beschreibung: <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>BNT162b2 by Pfizer-BioNTech and mRNA-1273 by Moderna are the most commonly used vaccines to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Head-to-head comparison of the efficacy of these vaccines in immunocompromised patients is lacking.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>Parallel, 2-arm (allocation 1:1), open-label, noninferiority randomized clinical trial nested into the Swiss HIV Cohort Study and the Swiss Transplant Cohort Study. People living with human immunodeficiency virus (PLWH) or solid organ transplant recipients (SOTR; ie, lung and kidney) from these cohorts were randomized to mRNA-1273 or BNT162b2. The primary endpoint was antibody response to SARS-CoV-2 spike (S1) protein receptor binding domain (Elecsys Anti-SARS-CoV-2 immunoassay, Roche; cutoff ≥0.8 units/mL) 12 weeks after first vaccination (ie, 8 weeks after second vaccination). In addition, antibody response was measured with the Antibody Coronavirus Assay 2 (ABCORA 2).</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>A total of 430 patients were randomized and 412 were included in the intention-to-treat analysis (341 PLWH and 71 SOTR). The percentage of patients showing an immune response was 92.1% (95% confidence interval [CI]: 88.4–95.8; 186/202) for mRNA-1273 and 94.3% (95% CI: 91.2–97.4; 198/210) for BNT162b2 (difference: -2.2%; 95% CI: -7.1 to 2.7), fulfilling noninferiority of mRNA-1273. With the ABCORA 2 test, 89.1% had an immune response to mRNA-1273 (95% CI: 84.8–93.4; 180/202) and 89.5% to BNT162b2 (95% CI: 85.4–93.7; 188/210). Based on the Elecsys test, all PLWH had an antibody response (100.0%; 341/341), whereas for SOTR, only 60.6% (95% CI: 49.2–71.9; 43/71) had titers above the cutoff level.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>In immunocompromised patients, the antibody response of mRNA-1273 was noninferior to BNT162b2. PLWH had in general an antibody response, whereas a high proportion of SOTR had no antibody response.</jats:p> </jats:sec>
- Zugangsstatus: Freier Zugang